AFM-Telethon has released the latest edition of its comprehensive document “Advances in Charcot-Marie-Tooth Disease”, offering patients, advocacy groups, and clinicians an exhaustive overview of the global scientific and clinical research landscape.
Publication Overview
Scientific Rigor & Accessibility: A thorough synthesis of current clinical trials, therapeutic pipelines, and genetic insights translated into clear, structured concepts for the rare disease community.
International Reach: Produced by the Scientific & Medical Information Department of AFM-Telethon in close collaboration with medical experts.
Multilingual Availability: Accessible in English, French, and through a localized 2026 Italian edition published by ACMT-Rete.
Understanding the fast-evolving landscape of therapeutic research is essential for patient empowerment and advocacy. The document “Advances in Charcot-Marie-Tooth Disease”, published by AFM-Telethon (the French Muscular Dystrophy Association), serves as an invaluable reference tool that bridges complex biomedical research and practical knowledge for patients and healthcare professionals.
Developed by AFM-Telethon’s dedicated medical information team in collaboration with leading clinical specialists, this publication details the state of research across all subtypes of Charcot-Marie-Tooth disease and related hereditary neuropathies.
Core Focus Areas Covered in the Guide
The document provides a structured review of scientific advancements, focusing on key areas critical to clinical trial readiness and therapeutic development:
In-depth updates on drug candidates, small molecules, gene therapy approaches (such as AAV-mediated gene replacement), and gene-silencing strategies targeting specific genetic subtypes including CMT1A, CMT2A, and CMTX1.
Analysis of active clinical trials, endpoint selection, and the identification of robust biological and MRI biomarkers necessary to accelerate regulatory approvals.
Insights into novel causative genes identified through next-generation sequencing (NGS), clarifying disease mechanisms and genetic classifications.
The strategic importance of global patient registries and observational studies in characterizing disease progression and establishing baseline data for trial design.
Empowering the European CMT Community and beyond
The European CMT Federation (ECMTF) actively promotes the dissemination of high-quality scientific literature across its member organizations. Initiatives like AFM-Telethon’s research guides align closely with ECMTF’s mission to foster scientific literacy, support international research collaboration, and ensure patient advocates are fully equipped to engage with academic and industry partners.
Access the Publication
Download the official English edition or explore translated versions made available through European partner organizations.
